Jodi Luchs, MD
Ophthalmology · West Palm Beach, FLNPI 1366413023
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Eyevance Pharmaceuticals LLC at 34.2% of the total. Reporting peaked in 2021 at $46,920 and has fallen 58.2% since, to $19,617 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 462 payments — averaging $447.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyevance Pharmaceuticals LLC$71K
- Bausch & Lomb Americas Inc.$50K
- Sun Pharmaceutical Industries Inc.$44K
- AbbVie$19K
- Thea Pharma Inc.$10K
- Alcon$2K
- plus $11K from 28 others
Across 10 payments — averaging $970.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Osmotica Pharmaceutical Corp.$5K
- AbbVie$5K
What the payments were for
- Consulting fees$84,01941%
- Speaking & faculty fees$91,93844%
- Travel & lodging$12,1086%
- Food & beverage$18,5609%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyevance Pharmaceuticals LLC | 104 | $70,729 |
| Bausch & Lomb Americas Inc. | 60 | $50,264 |
| Sun Pharmaceutical Industries Inc. | 70 | $43,964 |
| AbbVie(2 entities) | 79 | $18,632 |
| Thea Pharma Inc. | 14 | $10,469 |
| Alcon | 18 | $2,143 |
| Oyster Point Pharma, Inc. | 5 | $1,495 |
| Dompe US, Inc. | 10 | $1,425 |
| Sight Sciences, Inc. | 11 | $1,026 |
| Omeros Corporation | 1 | $1,000 |
| Shire North American Group Inc | 2 | $833 |
| Tearlab Corp | 1 | $700 |
| Rxsight Inc | 10 | $546 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $459 |
| Kala Pharmaceuticals, Inc. | 7 | $441 |
| Rayner Intraocular Lenses Limited | 5 | $397 |
| Tarsus Pharmaceuticals, Inc. | 12 | $391 |
| Novartis | 8 | $328 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $217 |
| Harrow Eye, LLC | 7 | $203 |
| Glaukos Corporation | 5 | $202 |
| LKC Technologies, Inc. | 1 | $149 |
| Aerie Pharmaceuticals, Inc. | 2 | $133 |
| Ocular Therapeutix, Inc. | 2 | $93 |
| ANI Pharmaceuticals, Inc. | 4 | $92 |
| Amgen(2 entities) | 3 | $66 |
| Optos, Inc. | 1 | $62 |
| Carl Zeiss Meditec, Inc. | 1 | $59 |
| Halozyme Inc | 1 | $39 |
| Johnson & Johnson Vision Care, Inc. | 1 | $38 |
| Eyepoint US, Inc. | 1 | $34 |
| Biotissue Holdings Inc. | 2 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $32 |
| NEW World Medical,inc. | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$46,580
- XIIDRA$32,751
- Flarex$27,228
- Tobradex ST$21,902
- CEQUA$21,782
- Zerviate$20,650
- BROMSITE$14,173
- VUITY$4,019
- IYUZEH$2,250
- XEN GLAUCOMA TREATMENT SYSTEM$1,525
- DURYSTA$1,504
- AzaSite$1,500
- TYRVAYA$1,360
- Clareon$1,309
- Oxervate$1,200
- OMIDRIA$1,000
- BLINK NUTRITEARS$850
- RESTASIS$788
- TearLab Osmolarity System$700
- OMNI(R) SURGICAL SYSTEM (US)$409
How this compares
$206,724 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 177 | $125,868 |
| LumiganBimatoprost | 166 | $57,727 |
| CombiganBrimonidine Tartrate/Timolol | 118 | $33,683 |
| ProlensaBromfenac Sodium | 76 | $24,620 |
| XiidraLifitegrast | 22 | $20,773 |
| Prednisolone Acetate | 457 | $16,179 |
| CequaCyclosporine | 20 | $11,191 |
| MieboPerfluorohexyloctane/Pf | 11 | $8,049 |
| Latanoprost | 735 | $6,954 |
| MoxifloxacinMoxifloxacin Hcl | 352 | $5,468 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 43 | $5,369 |
| Cyclosporine | 18 | $4,493 |
| RhopressaNetarsudil Mesylate | 13 | $3,898 |
| Timolol Maleate | 357 | $3,305 |
| Travoprost | 14 | $2,712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $18,632 | $217,278461 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $50,264 | $28,82233 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $217 | $24,62076 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $43,964 | $11,19120 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $133 | $3,89813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in West Palm Beach
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.